Last reviewed · How we verify
CT-L03
CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | CT-L03 |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-α inhibitor (biosimilar) |
| Target | TNF-α |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
CT-L03 is a monoclonal antibody that binds to and neutralizes TNF-α, a key pro-inflammatory cytokine. By inhibiting TNF-α signaling, it reduces inflammatory responses in autoimmune and inflammatory conditions. As a biosimilar, it is designed to have comparable efficacy and safety to the reference biologic adalimumab.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
Common side effects
- Injection site reactions
- Infections (including serious infections)
- Headache
- Nausea
Key clinical trials
- Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |